FDA Approves Sonrotoclax as First BCL2 Inhibitor for R/R Mantle Cell Lymphoma

BeOne Medicines announced that the U.S. Food and Drug Administration has granted accelerated approval to sonrotoclax for the treatment of adults with relapsed or refractory mantle cell lymphoma after at least two prior lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor. The approval makes sonrotoclax the first and only FDA-approved BCL2 inhibitor for mantle cell lymphoma, adding a new targeted option for patients in the challenging post-BTK inhibitor setting.

Mantle cell lymphoma is a rare, frequently aggressive subtype of non-Hodgkin lymphoma. Although many patients initially respond to therapy, relapse is common, and prognosis becomes more challenging after disease progression on BTK inhibitor-based treatment.

Sonrotoclax is described by BeOne Medicines as a next-generation BCL2 inhibitor designed to enhance potency and selectivity. The company says its pharmacologic profile may support improved efficacy, tolerability, and treatment convenience compared with earlier agents in the class.

“The data supporting the approval of sonrotoclax in the U.S. confirm its role as a foundational therapy for mantle cell lymphoma in the post-BTK inhibitor setting, and demonstrate that it can deliver robust disease control when treatment choices are limited and outcomes are poor. From a clinical perspective, this provides physicians with an important new option grounded in both efficacy and tolerability, fundamentally changing how we think about sequencing therapy in this disease,” said Dr. Michael Wang, Global Principal Investigator, Puddin Clarke Endowed Professor at The University of Texas MD Anderson Cancer Center,

Approval Based on Phase 1/2 BGB-11417-201 Data

The accelerated approval is supported by results from BGB-11417-201, a single-arm, multicenter Phase 1/2 trial evaluating sonrotoclax in adults with relapsed or refractory MCL. According to the FDA, efficacy was assessed in 103 patients who had previously received anti-CD20-based therapy and a BTK inhibitor.

Efficacy was established on the basis of overall response rate and duration of response, assessed by an independent review committee using Lugano criteria. Sonrotoclax achieved an overall response rate of 52% (95% CI, 42-62), with a complete response rate of 16% (95% CI, 9.1-24.0). Median time to response was 1.9 months.

Median duration of response was 15.8 months (95% CI, 7.4 months-not estimable), after an estimated median follow-up of 11.9 months. These findings indicate clinically meaningful activity in a difficult-to-treat post-BTK inhibitor population, although longer follow-up will be needed to further define durability of response.

Safety Profile and Dosing Considerations

The FDA prescribing information includes warnings and precautions for tumor lysis syndrome, serious infections, and neutropenia. Among 115 patients with MCL evaluated for safety, serious adverse reactions occurred in 37% of patients. Pneumonia was the most frequent serious adverse reaction, reported in 10%.

The recommended regimen begins with a four-week ramp-up phase to reduce the risk of tumor lysis syndrome. After ramp-up, patients receive sonrotoclax 320 mg orally once daily until disease progression or unacceptable toxicity.

Broader Development Program

Sonrotoclax has received FDA Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for this MCL indication. It has also received Fast Track Designation for Waldenström macroglobulinemia and Orphan Drug Designation for adult patients with Waldenström macroglobulinemia, multiple myeloma, acute myeloid leukemia, and myelodysplastic syndrome.

Sonrotoclax is already approved in China for relapsed or refractory MCL and for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received at least one systemic therapy, including a BTK inhibitor. Data from the R/R MCL program are also under review by the European Medicines Agency and other regulatory authorities.

“BeOne is leading the advancement and enhancement of BCL2 inhibition to revolutionize how we treat patients living with B-cell malignancies. Today’s approval of BEQALZI represents critical progress for patients with mantle cell lymphoma and reinforces our strategy of building foundational medicines designed to raise the standard of care in B-cell malignancies,” said Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines.

Sonrotoclax is being studied across a broad global development program involving more than 2,200 patients. Ongoing studies include monotherapy and combination strategies, including combinations with zanubrutinib in chronic lymphocytic leukemia, with updated data expected at the 2026 American Society of Clinical Oncology Annual Meeting.